DRL gets tentative USFDA nod for Alzheimer's drug
Dr Reddy's Laboratories Ltd has received tentative approval from the USFDA for the drug 'Rivastigmine' in capsule form.
By PTI |
MUMBAI: Dr Reddy's Laboratories Ltd has received tentative approval from the USFDA for the drug 'Rivastigmine' in capsule form.
The tentative approval was given to Rivastigmine Tartrate capsules for strengths of 1.5 mg, 3 mg, 4.5 mg, 6 mg, according to information on the USFDA website.
Rivastigmine is used for the treatment of Alzheimer's disease.
The tentative approval was given to Rivastigmine Tartrate capsules for strengths of 1.5 mg, 3 mg, 4.5 mg, 6 mg, according to information on the USFDA website.
Rivastigmine is used for the treatment of Alzheimer's disease.
Start a SIP with as low as ₹500 with ET Money App!
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
ADVERTISEMENT
